Jonathan Goldman, MD
(he/him)
Institutional Affiliation
Education
Fellowship
Internship
Degree
Residency
Board Certifications
Contact Information
Phone
Clinical Interests
Scientific Interests
Dr. Jonathan Goldman focuses on lung cancer research and early drug development.
Highlighted Publications
Goldman JW, Raju RN, Gordon GA, Vukovic VM, Bradley R, Rosen LS. A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. Submitted for review.
Goldman JW, Garon EB. Targeting MEK for the treatment of non-small cell lung cancer: a review from the 12th annual targeted therapies of treatment of lung cancer. Journal of Thoracic Oncology, 2012.
Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012 Dec 1;118(23):5903-11. doi: 10.1002/cncr.27575. Epub 2012 May 17.
Ralli M, Goldman JW, Lee E, Pinter-Brown LC, Glasgow BJ, Sarraf D. Intraocular involvement of mycosis fungoides. Arch Ophthalmol. 2009 Mar;127(3):343-5.
O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, Pommier Y. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun. 1991 Aug;3(8):233-40.
